Abstract
Dementia is characterized by the progressive degeneration of cognitive abilities. Understanding these changes is vital for determining how structural brain alterations affect cognition and for facilitating early detection. While disease progression models (DPMs) are often used to reconstruct longitudinal trajectories from cross-sectional data, existing models—primarily designed for brain imaging—frequently rely on Gaussian assumptions that do not translate well to cognitive data. This paper introduces Kernel Density Estimation Mixture Modelling (KDEMM), a non-parametric approach that accurately models non-normally distributed cognitive test data. Our results demonstrate that KDEMM outperforms traditional Gaussian Mixture Models (GMMs) in both simulated and clinical datasets, providing a more accurate reflection of clinical phenotypes in Alzheimer’s disease subtypes.
The Challenge: Why Gaussian Models Fail Cognitive Data
To map the long-term progression of diseases like Alzheimer’s, researchers utilize Event-Based Models (EBMs). These models determine the sequence in which biomarkers transition from a "healthy" to a "diseased" state. Traditionally, EBMs employ Gaussian Mixture Models (GMMs) to define these states.
However, cognitive test scores rarely follow a normal distribution. They are often plagued by "ceiling effects" (where healthy individuals achieve perfect scores) and "floor effects" (where impaired individuals score zero), resulting in highly skewed or bimodal distributions. Forcing this "messy" data into a Gaussian framework often leads to inaccurate disease timelines that contradict clinical reality.
Methodology: The KDEMM Approach
The core innovation of this work is the replacement of parametric GMMs with Kernel Density Estimation (KDE). Unlike GMMs, which assume a specific mathematical shape (the bell curve), KDE creates a smooth silhouette of the data's actual distribution, regardless of its skewness or complexity.
The authors developed an iterative algorithm to fit these models:
- Update Step: Fitting a KDE to subsets of the data to define the healthy and diseased distributions.
- Assignment Step: Re-assigning individual data points to either the healthy or diseased group based on which KDE provides a better fit.
Experimental Validation
The model was evaluated using both synthetic and clinical data:
- Simulated Data: 5,000 synthetic subjects were generated using Gamma distributions to test the model against a known "ground truth" with varying levels of data skewness.
- Clinical Data: A dataset from the Dementia Research Centre (London) included patients with Posterior Cortical Atrophy (PCA) (a visual-led variant) and typical Alzheimer’s disease (tAD) (memory-led), alongside healthy controls.
Key Results and Clinical Insights
- Superior Accuracy: In simulations, KDEMM achieved a significantly higher correlation with the ground truth sequence (Kendall’s $\tau = 0.89$) compared to the GMM ($\tau = 0.50$). It also proved more reliable at staging patients, with a correlation of $\rho = 0.88$ versus the GMM’s $0.83$.
- Clinical Alignment: In the PCA cohort, KDEMM correctly identified visual impairment events (e.g., failing "dot counting" tests) as occurring earlier in the disease timeline than memory loss. In contrast, the GMM produced a sequence that was clinically nonsensical.
- Model Stability: Bootstrapping analysis revealed that KDEMM produces much more consistent timelines across different data subsets, whereas GMMs were prone to "jitter," with biomarkers shifting positions unpredictably.
Conclusion
KDEMM represents a significant advancement in disease progression modelling for non-normally distributed data. By moving away from rigid parametric assumptions, researchers can more accurately integrate cognitive test batteries into complex models. Future work will focus on combining KDEMM with imaging and fluid biomarkers to create holistic, multi-modal maps of neurodegenerative decline.
Summary updated